Welcome to our dedicated page for Roivant Sciences news (Ticker: roivw), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences stock.
Riovant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on accelerating the development and commercialization of medicines that matter. The company's pipeline includes VTAMA®, a topical treatment for psoriasis and atopic dermatitis, IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor in autoimmune indications, and brepocitinib, a small molecule inhibitor for dermatomyositis and non-infectious uveitis. Through creating nimble subsidiaries, Roivant aims to advance its therapies and technologies, while also nurturing discovery-stage companies and health tech startups.
Rhea-AI Summary
Roivant (Nasdaq: ROIV) completes the acquisition of Telavant by Roche (SIX: RO, ROG; OTCQX: RHHBY) for $7.1 billion, with an upfront payment and a near-term milestone payment. Telavant holds rights to RVT-3101, a therapy for inflammatory bowel disease in the US and Japan. Roivant previously owned 75% of Telavant's shares. Roche aims to continue RVT-3101's development across multiple indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
Immunovant, Inc. (IMVT) announced initial data from the 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402, showing that four subcutaneously administered doses of 600 mg produced a mean IgG reduction similar to high dose batoclimab, with minimal changes in albumin and LDL-C, confirming the potential of IMVT-1402 as a best-in-class FcRn inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Roivant (ROIV) and Priovant announce that the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 (SRI-4) at Week 52. However, Priovant plans to continue progressing the program in indications outside of Systemic Lupus Erythematosus (SLE) due to the drug’s favorable safety and tolerability profile, six other positive phase 2 studies, and active arm performance in this study. Priovant also expects to announce topline results from the Phase 2 POC study of brepocitinib in non-infectious uveitis (NIU) in the first quarter of calendar year 2024 and topline results from the Phase 3 trial in dermatomyositis (DM) in calendar year 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Roivant (ROIV) reported a definitive agreement with Roche for the sale of Telavant for $7.1B upfront and a milestone payment of $150M. IMVT-1402 SC doses achieved peak IgG reductions similar to batoclimab. VTAMA® cream generated $18.4M in net product revenue for the quarter. Cash, cash equivalents, and restricted cash were approximately $1.4B at September 30, 2023, expected to reach $7.0B with pending sale proceeds. Mayukh Sukhatme, M.D. appointed to the Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Roivant (Nasdaq: ROIV) appoints Mayukh Sukhatme, M.D., as a new member of its Board of Directors, expanding the board to eight members. Dr. Sukhatme's extensive experience in the pharmaceutical industry and his role in driving positive Phase 3 studies and FDA approvals make him a valuable addition to the board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Roivant (Nasdaq: ROIV) will host a live conference call and webcast on November 13, 2023, to report its Q2 2023 financial results and provide a business update. The conference call will be accessible via phone registration and the webcast will be available on the Roivant website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Roche has entered into a definitive agreement with Roivant to acquire Telavant Holdings, gaining the rights to develop and commercialize RVT-3101, a novel TL1A directed antibody for the treatment of inflammatory bowel disease. Roche will pay a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million. The agreement also includes an option for a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IMVT-1402 subcutaneous doses showed dose-dependent reductions in IgG with no adverse effects on serum albumin or LDL-C levels. Initial data supports IMVT-1402 as a potential best-in-class FcRn inhibitor. Mean total IgG reduction from baseline in the 300 mg MAD cohort was 63%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Roivant completes redemption of outstanding warrants at $0.10 per warrant
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Roivant announces the Redemption Fair Market Value for its outstanding public and private placement warrants. The Redemption Fair Market Value is $11.35 per warrant. Holders who exercise their warrants on a cashless basis will receive approximately 0.2495 common shares per warrant. The redemption price for the warrants is $0.10 per warrant. The warrants will cease trading on the redemption date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is Roivant Sciences Ltd. focused on?
Roivant Sciences Ltd. is focused on accelerating the development and commercialization of medicines that matter, with a pipeline of innovative treatments for various conditions.
What are some products in Roivant Sciences Ltd.'s pipeline?
Roivant Sciences Ltd.'s pipeline includes VTAMA®, IMVT-1402, batoclimab, and brepocitinib, targeting autoimmune diseases and other conditions.
How does Roivant Sciences Ltd. advance its pipeline?
Roivant Sciences Ltd. advances its pipeline by creating nimble subsidiaries or 'Vants' to develop and commercialize its medicines and technologies.
What additional initiatives does Roivant Sciences Ltd. undertake?
In addition to therapeutics, Roivant Sciences Ltd. incubates discovery-stage companies and health technology startups that complement its biopharmaceutical business.
What is the significance of Roivant Sciences Ltd.'s latest achievements?
Roivant Sciences Ltd. has recently achieved positive results in Phase 2 studies, such as the NEPTUNE study, showing the efficacy of brepocitinib in non-anterior non-infectious uveitis, indicating potential transformative benefits for patients.
Roivant Sciences